Women with a history of cardiotoxicity from previous cancer treatments are around 30 percent more likely to experience clinical congestive heart failure (CHF) before, during or after pregnancy, according to research published ahead of print in the Journal of the American College of Cardiology.

A deep-learning software that can automatically calculate left ventricular ejection fraction (LVEF) with less variability than a cardiologist recently received approval from the U.S. Food and Drug Administration (FDA).

The American Society of Echocardiography (ASE) announced Jan. 29 its ImageGuideEcho registry is open to U.S. physicians. ImageGuideEcho is the first registry exclusively devoted to measuring quality in cardiovascular ultrasounds.

Cardiologists are receiving more exposure to different imaging modalities during their fellowships, but their job prospects and training vary widely. A more comprehensive and multimodality training approach could lead to better results.  

As life expectancy continues to expand for cancer patients, clinicians are increasingly dealing with oncological complications like cardiotoxicity, according to a medical team in the Netherlands—and those doctors are met with a paucity of research on the topic.

Premium cardiac and vascular imaging rises to a new standard as Hitachi Healthcare Americas introduces the new premium 2D and 3D cardiovascular ultrasound system, the LISENDO 880, at the American Society of Echocardiography 2017 in Baltimore, Maryland on June 3rd, 2017.

When advanced cardiac ultrasound imaging is needed for fast and confident diagnoses, Toshiba Medical, a Canon Group company, will showcase its AplioTM i900 at this year’s American Society of Echocardiography (ASE) 2017 annual meeting in Baltimore, Md., June 2–6, 2017 (Booth #313). The Aplio i900 system is the latest addition to the premium Aplio i-series ultrasound platform, providing cardiologists and cardiovascular sonographers an ultrasound solution with excellent imaging clarity and definition.